By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...

Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more ...

Even after completing treatment for tuberculosis (TB), some patients may remain vulnerable to further lung infections.

Gujarat BJP MP Babubhai Jesangbhai Desai on Friday raised alarm in the Rajya Sabha over the rising incidence of lung cancer ...

Adding fan-to-face therapy to a supervised exercise training program lowers exertional breathlessness across training ...

As the nation recognizes Women’s History Month, Illinois health leaders have launched a renewed, statewide effort to increase ...

While smoking remains the leading risk factor, other contributors include secondhand smoke, air pollution, radon exposure and ...

The biopharma company will now seek Arikayce’s approval in the US and Japan for use in earlier lines of treatment.

Lung cancer is often misunderstood, leading to delayed diagnosis and missed treatment opportunities. Experts debunk myths ...